Organization | Beijing Doing Biomedical Co., Ltd.

Beijing Doing Biomedical Co., Ltd. Report issue

For profit Phase 1 Phase 2

Founded: Beijing China (2005)

Status: Acquired by China National Biotec Group Co., Ltd (2010)

Organization Overview

First Clinical Trial

2015

NCT02585908

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2017

Timeline

NOW

Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Beijing Doing Biomedical Co., Ltd.

Active Ingredients

Drugs in Phase 2 Trials (2)

cytokine induced killer cells (1 trial)

gamma-delta t cells (1 trial)

Drugs in Phase 1 Trials (5)

anti-cd19-car gamma-delta t cells (1 trial)

autologous humanized anti-cd19 and anti-cd20 dual specific car-t cells (1 trial)

cd19 car-t cells (1 trial)

muc1-gene-dc-ctl (1 trial)

muc1-peptide-dc-ctl (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Lymphoma (Phase 1)

Stomach Neoplasms (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 5
# of Trial APIs: 7